Hubei Guangji Pharmaceutical Co., Ltd.

000952

CNE0000010R5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
6.22 ^CNY	-2.05%		-13.85%	-22.15%

04-25	Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-25	Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Guangji Pharmaceutical Co. Ltd. announced that it has received CNY 180 million in funding from Hubei Guangji Pharmaceutical Co., Ltd.

December 01, 2021

On December 2, 2021, Guangji Pharmaceutical (Mengzhou) Co. Ltd. closed the transaction. The registered capital of the company increased to CNY 389,534,883.72.

Latest news about Hubei Guangji Pharmaceutical Co., Ltd.

Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Guangji Pharmaceutical Gets Nod to Produce Entecavir	11-07	MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	20/10/23	CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23	CI
Guangji Pharma to Establish Joint Innovation Laboratory With Jiangnan University	15/06/23	MT
Guangji Pharma to Borrow 281 Million Yuan From Bank to Support Acquisition Deals	17/05/23	MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Hubei Guangji Pharmaceutical Announces Profit Distribution Proposal for 2022	20/04/23	CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	19/04/23	CI
Guangji Pharma Registers Diabetes-Related Infection Drug	29/03/23	MT
Hubei Guangji Pharma to Invest 468 Million Yuan in Parkson Biotechnology Amid Bankruptcy Reorganization	08/02/23	MT
Hubei Guangji Pharma Signs 6MW Solar Power Project	15/12/22	MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Guangji Pharmaceutical Unit to Resume Production After Three-Month Stoppage	04/10/22	MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	18/08/22	CI
Hubei Guangji Pharmaceutical Jikang Medicine Co., Ltd. announced that it has received CNY 45 million in funding from Hubei Guangji Pharmaceutical Co., Ltd.	18/07/22	CI
Hubei Guangji Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for the Year 2021, Payable on May 27, 2022	19/05/22	CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
Hubei Guangji Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021	21/04/22	CI
Hubei Guangji Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Year 2021	25/03/22	CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	24/03/22	CI
Guangji Pharmaceutical Co. Ltd. announced that it has received CNY 180 million in funding from Hubei Guangji Pharmaceutical Co., Ltd.	01/12/21	CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	22/10/21	CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	18/08/21	CI

Chart Hubei Guangji Pharmaceutical Co., Ltd.

Duration

Period

Chart Hubei Guangji Pharmaceutical Co., Ltd.

More charts

Hubei Guangji Pharmaceutical Co., Ltd. is the Chinese leader of pharmaceutical ingredients production. The group's activity is organized around four product families: - vitamins: riboflavin and beta carotene; - food supplements; - fine chemistry products; - medicinal preparations.

Sector

Pharmaceuticals

Calendar

29/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUBEI GUANGJI PHARMACEUTICAL CO., LTD.	-22.15%	311M
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals

Hubei Guangji Pharmaceutical Co., Ltd.

Equities

000952

CNE0000010R5

Pharmaceuticals

Guangji Pharmaceutical Co. Ltd. announced that it has received CNY 180 million in funding from Hubei Guangji Pharmaceutical Co., Ltd.

Latest news about Hubei Guangji Pharmaceutical Co., Ltd.

Chart Hubei Guangji Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals